Register today to join our live webinar on April 12th. During our virtual event, HCP attendees will have the opportunity to submit questions to our faculty. 

Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC Considerations for dosing, administration, and patient counseling

Exploring a treatment option for patients with previously treated Metastatic Small Cell Lung Cancer

Join the Baylor College of Medicine for the 

4th Annual Acute Hematologic Malignancies Symposium

This symposium will bring together recognized national and international speakers to address recent advances in diagnosis of myelodysplastic syndrome (MDS) and measurable residual disease [MRD] directed acute myelogenousleukemia (AML) therapy 

The symposium is intended for hematologists, primary care physicians, nurses, nurse practitioners, physician assistants, medical trainees, and students

Registration is required via the Baylor College of Medicine website.

For three days, we will broadcast a series of interviews with top thought leaders to share their insights and reactions to data presented during the hybrid Genitourinary Cancers Symposium. 

Register today and tune in for our exclusive broadcasts each evening at 8:00PM EST.

OncLive® News Network: On Location at ASCO GU 2022

TOPICS OF DISCUSSION AT THIS VIRTUAL EVENT INCLUDE:

Discuss approaches for adverse event management in patients with CLL who are receiving BTK inhibitors

Promoting medication adherence and continuation of therapy in patients with CLL

Updates in CLL: Strategies for Managing Toxicities and Special Patient Considerations

Topics of discussion at this virtual event will include:

Gain insights into factors guiding treatment selection in non-small cell lung cancer (NSCLC) lacking actionable genetic alterations

Review safety and efficacy data of immune checkpoint inhibitors in first-line treatment of metastatic NSCLC

Discuss treatment decision-making based on PD-L1 expression levels in NSCLC

Immune Checkpoint Inhibitors in First-line Treatment of Metastatic NSCLC

Clinical data supporting a treatment option for patients with intermediate-2 or high-risk myelofibrosis

NCCN Clinical Practice Guidelines surrounding use of a treatment option in myelofibrosis

Safety, adverse event management, and dose modifications

Steps for starting your patients on this treatment option

A treatment option for patients with Myelofibrosis

Review the landscape of small cell lung cancer and factors that make it an aggressive disease

Compare and contrast the first-line therapy options

Obtain insight on strategies for monitoring patient response to treatment.

Discuss second-line therapy options and indicators to change therapy.

Updates in SCLC: Advances in Treatment

Review techniques, including radiopharmaceuticals-based imaging techniques, for characterizing estrogen receptor status in metastatic breast cancer

Discuss best practices for radiopharmaceuticals-based imaging in metastatic breast cancer

Obtain insights on strategies for identifying the appropriate patients with breast cancer for radiopharmaceuticals-based imaging

Gain expert perspectives on how the application of radiopharmaceuticals-based imaging can improve clinical outcomes in metastatic breast cancer

Optimizing Imaging in Metastatic Breast Cancer to Improve Clinical Outcomes

Topics of discussion at this virtual event include:

A Treatment Option for Patients with Myelofibrosis

Register for our interactive event featuring leading 

 experts engaging in an educational discussion on topics designed to improve patient outcomes.

During this live event, our faculty will:

Discuss the evolving treatment landscape in CLL and recent data updates

Review novel therapies and combinations being studied for the treatment of patients with CLL

Obtain insight on how new and novel therapies may impact the treatment landscape in the future

Updates in CLL: What’s on the Horizon in CLL?

Review testing standards in the frontline and relapsed setting for patients with CLL

Discuss the importance and clinical utility of testing for the selection of treatment in patients with CLL

Obtain expert insight on testing strategies and processes

Updates in CLL: An In-Depth Look at Testing Strategies

Topics of discussion at this event include:

Historical clinical trial eligibility considerations in advanced NSCLC

Clinical evidence, safety profile, and post-hoc and exploratory analyses from one of the largest advanced NSCLC clinical trials conducted to date

Resources to help support your eligible patients

FDA approved first-line monotherapy option in advanced NSCLC

NCCN Clinical Practice Guidelines surrounding use of a treatment option in myelofibrosis

Review the role of BTKi in the management of chronic lymphocytic leukemia (CLL)

Take an in-depth look at adverse events associated with BTKi with a focus on cardiotoxicity

Obtain insight on strategies for monitoring and management and the potential impact on subsequent therapy selection

Discuss the role of advanced practice practitioners, nurses, and other medical professionals in the care of patients with CLL

Updates in CLL: A Closer Look at Adverse Events

NCCN Clinical Practice Guidelines surrounding use of the new treatment option in myelofibrosis

This presentation will illustrate the broad range of tests currently available in breast cancer, the circumstances under which they may be used, and the therapeutic implications of their results.

Outline the recommendations from current breast cancer guidelines around biomarker testing

Detail the range of tests available for biomarker testing in breast cancer

Understand the current (vs. ideal) frequency of biomarker testing in breast cancer

Learn how all breast cancer testing can be done through ONE lab

Providing the Diagnostics You Need in Breast Cancer Care with One Lab

Join us for this expert-led program where we will explore:

Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC

Considerations for dosing, administration, and patient counseling

Exploring a Treatment Option for Patients With Previously Treated Metastatic Small Cell Lung Cancer (SCLC)

Key efficacy and safety data, as well as dosing information

Clinical insights, shared through a live Q&A session

1L Metastatic NSCLC National Webcast Series

Topics of discussion at this virtual event:

Provide an overview of the AYVAKIT prescribing information, including clinical trial data, safety information, and dosing recommendations

Discuss hypothetical patient cases based on clinical trial experience

AYVAKIT™ (avapritinib): The only targeted therapy for Advanced Systemic Mastocytosis designed for potent and selective inhibition of KIT D816V1  

Topics of discussion at this virtual event: Part 2 Series

Opportunities borne from effective screening

Effective screening-to-treatment plans: what does it look like for a patient?

Lung Cancer Screening & Treatment: What Comes Next?

Identify the role of NGS and frequency of incidental germline findings in tumor testing

Examine the value of tumor/normal sequencing for metastatic cancer patients with incidental germline findings

Obtain insight on how physicians interpret incidental germline findings and the impact on decision making

The Evolving Role of NGS and Germline Sequencing in Patients with Advanced and Metastatic Cancer

Clinical trial data for first-line monotherapy in patients with advanced NSCLC with PD-L1 ≥50%, based on one of the largest studies in this setting

Efficacy and safety findings from clinical trials in advanced CSCC and locally advanced BCC

Detailed patient cases from clinical trials

A Treatment Option for Advanced NSCLC and two types of Advanced Skin Cancers

As the treatment landscape for ALK-positive metastatic non-small cell lung cancer continues to take shape, extended analyses of clinical trial data may offer additional clinical insight on the utility of approved therapies.

, will share a case study in ALK-positive non-small cell lung cancer and discuss recent study findings for an available treatment option. Additionally, they will take questions and share clinical perspective through a live question and answer session.

To obtain clinical perspective and learn about how these results may impact your patients and your practice, watch the live broadcast on 

Wednesday, 5/26 at 6:00pm ET or 8:00pm ET; or on Wednesday, 6/16 at 12:00pm ET or 3:00pm ET

https://studio.mjhassoc.com/reach/takedaoncbroadcast

Upcoming Live Broadcast to Feature Recent Data and Case Study in ALK+ Metastatic NSCLC

Recent research and trends into lung cancer screening

The effect of COVID-19 on lung cancer screening

The US Preventive Services Task Force 2021 Lung Cancer Screening Guidelines: key takeaways, what’s new, etc.

Lung Cancer Screening & Treatment After COVID-19

OncLive® News Network: On Location at ASCO 2021

Join this live virtual event to discuss new data for OPDIVO

Review the role of MRD detection in GI cancer

Explore how the role of MRD is evolving and how this will inform physicians in the future

Discuss the potential impact MRD monitoring and detection has on patients

 Please join us to learn about The Impact of Minimal Residual Disease in Cancer

Join us for our 8th Annual Joseph Calello Melanoma Scholar virtual lecture with Dr. Charles M. Balch, who has led a distinguished career as a clinical and academic surgical oncologist for the past 41 years as a leading authority in both melanoma and breast cancer.

Dr. Charles M. Balch
Professor, Department of Surgical Oncology - Research, Division of Surgery,
The University of Texas MD Anderson Cancer Center, Houston, TX

8th Annual Joseph Calello Melanoma Scholar Lecture: A Virtual Presentation on The Surgical Management of Melanoma

Clinical evidence from one of the largest advanced NSCLC trials conducted to date

Please join us to learn about a new FDA-approved first-line monotherapy option in advanced NSCLC

A new FDA-approved systemic treatment option

The important role of multidisciplinary consultation in the management of advanced BCC

Results and case studies from a prospective clinical study in locally advanced BCC patients

Mark Agulnik, MD
Section Chief, Sarcoma Oncology H&N Program
City of Hope Medical Center-Duarte, CA

Please join us to learn about the multidisciplinary management of advanced BCC

 OncLive® News Network: On Location - ASCO GU 2021

OncLive® News Network: On Location - ASCO GI 2021

Join OncLive® on December 17th, at 3:00 pm and 5:00 pm EST, to gain insights from leaders from organizations such as West Cancer Center and Stanford Cancer Centers as they discuss shifting treatment paradigm in mBC, and their approach to ensuring success with oral therapy.

New Pathways and Chemotherapeutic Delivery Mechanisms in the Treatment of Metastatic Breast Cancer

What is the rationale and strategy for implementing chemotherapy-free intervals for patients with metastatic colorectal cancer? Join us as our panel of renowned experts, Dr. John Marshall and Dr. Axel Grothey discuss this critical topic and answer your questions.

Incorporating a Chemotherapy-Free Interval in Metastatic Colorectal Cancer

OncLive News Network: On Location — SABCS 2020

OncLive® News Network: On Location – ASH 2020

Join us to learn more about how to navigate the new role of immunotherapy in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer on Thursday, December 3, 2020 at 8:00 PM EST.

First-Line Extensive-Stage Small Cell Lung Cancer: Examining the New Role of Combination Chemotherapy and Immunotherapy

We are pleased to announce the Eighth Annual Giants of Cancer Care

 class of inductees. Join us to honor these 15 individuals for their unmatched genius, their generous compassion, and the countless hours of work they have sacrificed to help their patients.

8th Annual Giants of Cancer Care Awards Ceremony

Join us for a presentation on an FDA-approved treatment option to better treat your patients with advanced cutaneous squamous cell carcinoma 

on Thursday, November 5, 2020 at 7:00 PM EDT.

An FDA-approved treatment option in patients with Advanced Cutaneous Squamous Cell Carcinoma

During this live broadcast, you'll learn about XPOVIO® (selinexor), including an overview of:

Michael W. Schuster, MD, and Hakan Kaya, MD

Join Us to Learn About XPOVIO

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Mohammad Jahanzed, MD, FACP, FASCO, and Reshma L. Mahtani, DO, on Monday, October 26, 2020 at 8 PM EDT.

Therapeutic Considerations in Metastatic HER2+ Breast Cancer

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Mark Daniel Pegram, MD and Julie R. Gralow, MD, on Thursday, October 15, 2020 at 8:00 PM PDT.

Considerations in Metastatic HER2+ Breast Cancer

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Debu Tripathy, MD and Michelina Cairo, MD, on Tuesday, October 13, 2020 at 8:00 PM CDT.

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Sara Tolaney, MD, MPH, and Komal Jhaveri, MD, FACP, on Wednesday, October 7, 2020 at 8 PM EDT.

Join us to learn more about how the field in HER2+ breast cancer is evolving and hear direct from leading experts, Hope Rugo, MD and Sara Hurvitz, MD on Wednesday, October 7, 2020 at 7:30 PM PDT.

In this Onclive® webinar, leading lymphoma experts will discuss the use of new and emerging treatment options for relapsed/refractory diffuse large B-cell lymphoma and how these treatments can help shape individualized treatment plans. Join us Tuesday, September 15, 2020 at 8 PM EDT.

A New Chapter in DLBCL: Uncovering New Treatment Options For Your Patients

In this Onclive® webinar, leading experts will highlight how the field in HER2+ breast cancer is evolving and hear direct from leading experts. Join us Tuesday, September 15, 2020 at 8 PM EST.

Register for our live webinar to gain insights and expert perspectives on 

 (NSCLC) treatment landscape. Our virtual event allows HCP participants to submit questions directly to our faculty.



Take an in-depth look at antibody drug conjugate (ADC) technology and those that are in the pipeline for NSCLC

Gain insight on how ADCs have the potential to impact the treatment landscape of NSCLC

Review strategies for managing adverse events associated with ADCs in NSCLC

On the Horizon in NSCLC: Antibody Drug Conjugates

Register today to join our live webinar on June 16th. During our virtual event, HCP attendees will have the opportunity to submit questions to our faculty. Secure you virtual seat today.

Discuss practice patterns and data supporting use of front-line immune checkpoint inhibitors in patients with advanced NSCLC

Identify appropriate patient populations for use of dual immune checkpoint inhibitor regimens

Examine treatment options for patients with low or no PDL-1 expression

Webinars